Idris Bahce

Idris Bahce

Auto-generated profile, based on publicly available information

Idris Bahce

VU University Medical Center, Amsterdam/NL

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
IBIdris Bahce
Idris Bahce
ESEgbert F. Smit
Egbert F. Smit
MLMark Lubberink
Mark Lubberink
AVAstrid A. M. van der Veldt
Astrid A. M. van der Veldt
MYMaqsood Yaqub
Maqsood Yaqub
NHN. Harry Hendrikse
N. Harry Hendrikse
Purpose: To evaluate whether, in patients with non–small cell lung carcinoma (NSCLC), tumor uptake of [11C]erlotinib can be quantified and imaged using positron emission tomography and to assess whether the level of tracer uptake corresponds with the presence of activating tumor EGF receptor (EGFR) mutations.

1 May 2017 in Lung Cancer
Verified
Journal Article
Open access
IBI. Bahce
I. Bahce
MYM. Yaqub
M. Yaqub
ESE.F. Smit
E.F. Smit
Adriaan Anthonius LammertsmaAdriaan Anthonius Lammertsma
Adriaan Anthonius Lammertsma
GDG.A.M.S. van Dongen
G.A.M.S. van Dongen
NHN.H. Hendrikse
N.H. Hendrikse
Non-small cell lung cancer (NSCLC) therapy has entered a rapidly advancing era of precision medicine with an ever increasing number of drugs directed against a variety of specific tumor targets. Amongst these new agents, tyrosine kinase inhibitors (TKIs) and monoclonal antibodies (mAbs) are most frequently used. However, as only a sensitive subgroup of patients benefits from targeting drugs, predictive biomarkers are needed. Positron emission tomography (PET) may offer such a biomarker for predicting therapy efficacy. Some of the TKIs and mAbs that are in clinical use can be radioactively labeled and used as tracers. PET can visualize and quantify tumor specific uptake of radiolabeled targeting drugs, allowing for characterization of their pharmacokinetic behavior. In this review, the clinical potential of PET using radiolabeled TKIs (TKI-PET) and mAbs (immuno-PET) in NSCLC is discussed, and an overview is provided of the most relevant preclinical and clinical studies.

9 February 2016 in EJNMMI Research
Verified
Journal Article
Open access
PDF file
IBIdris Bahce
Idris Bahce
MYMaqsood Yaqub
Maqsood Yaqub
HEHanane Errami
Hanane Errami
RSRobert C. Schuit
Robert C. Schuit
PSPatrick Schober
Patrick Schober
NHN. Harry Hendrikse
N. Harry Hendrikse
In non-small cell lung cancer (NSCLC) patients off erlotinib therapy, positron emission tomography (PET) using [11C]erlotinib distinguished epidermal growth factor receptor (EGFR) mutations from wild-type EGFR. However, tumor uptake of [11C]erlotinib during erlotinib therapy is unknown. Therefore, the aims of this study were to evaluate tumor [11C]erlotinib uptake in NSCLC patients both on and off erlotinib therapy, to evaluate the effect of erlotinib therapy on tumor perfusion and its correlation to tumor [11C]erlotinib uptake, and also, to investigate simplified uptake parameters using arterial and venous blood samples. Ten patients were to be scanned twice with a 1–2-week interval, i.e., on (E+) and off (E−) erlotinib therapy. Each procedure consisted of a low-dose CT scan, a 10-min dynamic [15O]H2O PET scan, and a 60-min dynamic [11C]erlotinib PET scan with arterial and venous sampling at six time points. In patients(E+), the optimal compartment model was analyzed using Akaike information criterion. In patients(E−), the uptake parameter was the volume of distribution (V T), estimated by using metabolite-corrected plasma input curves based on image-derived input functions and discrete arterial and venous blood samples. Tumor blood flow (TBF) was determined by rate constant of influx (K1) of [15O]H2O using the 1T2k model and correlated with V T and K1 values of [11C]erlotinib. The investigated simplified parameters were standardized uptake value (SUV) and tumor-to-blood ratio (TBR) at 40–60 min pi interval. Of the 13 patients included, ten were scanned twice. In patients(E+), [11C]erlotinib best fitted the 2T4k model with V T. In all patients, tumor V T(E+) was lower than V T(E−) (median V T(E−) = 1.61, range 0.77–3.01; median V T(E+) = 1.17, range 0.53–1.74; P = 0.004). Using [15O]H2O, five patients were scanned twice. TBF did not change with erlotinib therapy, TBF showed a positive trend towards correlation with [11C]erlotinib K1, but not with V T. TBR40–50 and TBR50–60, using both arterial and venous sampling, correlated with V T(E−) (all r s >0.9, P < 0.001), while SUV did not. In patients off and on therapy, venous TBR underestimated arterial TBR by 26 ± 12 and 9 ± 9 %, respectively. In patients on erlotinib in therapeutic dose, tumor V T decreases with high variability, independent of tumor perfusion. For simplification of [11C]erlotinib PET scanning protocols, both arterial and venous TBR 40–60 min post injection can be used; however, arterial and venous TBR values should not be interchanged as venous values underestimate arterial values. Registered at the Netherlands Trial Registry: NTR3670 .

20 May 2011 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
ESE. F. Smit
E. F. Smit
MLM. Lubberink
M. Lubberink
IBI. Bahce
I. Bahce
MWM. Walraven
M. Walraven
MBM. P. de Boer
M. P. de Boer
AVA. A. van der Veldt
A. A. van der Veldt
3059 Background: Current strategies combining anti-angiogenic drugs with chemotherapy provide clinical benefit in patients with advanced-stage NSCLC cancer. It has been hypothesized that pre-treatment with anti-angiogenic drugs may transiently normalize abnormal tumor vasculature and contribute to improved delivery of subsequent chemotherapy (Nat Med 2001;7:987-9). The purpose of the present study was to investigate this concept in NSCLC patients using a perfusion tracer ([15O]H2O), radiolabeled chemotherapy ([11C]docetaxel) and positron emission tomography (PET) before and after a single infusion of bevacizumab. Methods: A total of 70 PET scans were scheduled in 10 NSCLC patients. Patients underwent dynamic PET scans with [15O]H2O and [11C]docetaxel before, and at 5 hours and 4 days after IV administration of bevacizumab (15 mg·kg-1). An additional [15O]H2O scan was performed at 2 hours. Systemic effects of bevacizumab were investigated by assessing: (1) plasma levels of vascular endothelial growth factor (VEGF) using ELISA kits, (2) blood pressure, (3) cardiac output using [15O]H2O, and (4) microcirculation in the skin using capillaroscopy. Results: Two hours after bevacizumab administration, tumor perfusion did not change (Wilcoxon Signed Ranks test , P = 0.89). At 5 hours, however, both tumor perfusion and the net influx rate constant of [11C]docetaxel decreased significantly (P < 0.05 for both). These changes persisted until day 4 (P < 0.01 for both). Changes in tumor parameters were accompanied by a rapid decrease in circulating VEGF at 3 hours (P < 0.05) and a decline in cardiac output at 4 days (P = 0.05). The other systemic parameters remained unchanged. Conclusions: A single dose of bevacizumab induces a rapid and significant decline in tumor perfusion and [11C]docetaxel delivery in NSCLC tumors. These rapid changes in tumor parameters are not due to changes in cardiovascular parameters. The findings of the present study highlight the importance of drug scheduling for enhancing drug delivery to tumors and advocate further studies to optimize scheduling of anti-angiogenic drugs.

1 November 2017 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
PDF file
ANA. Niemeijer
A. Niemeijer
ESE. Smit
E. Smit
GDG. Van Dongen
G. Van Dongen
AWA.D. Windhorst
A.D. Windhorst
MHM. Huisman
M. Huisman
JLJ. De Langen
J. De Langen

1 November 2017 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
PDF file
AGA.L. Görtz
A.L. Görtz
SFS. Finn
S. Finn
LBL. Bubendorf
L. Bubendorf
IBI. Bahce
I. Bahce
BWB. Witte
B. Witte
ETE. Thunnissen
E. Thunnissen